Nivestim – pro
Nivestim is a ‘biosimilar’ medicine. This means that Nivestim is similar to a biological medicine (the ‘reference medicine’) that is already authorized. The reference medicine for Nivestim is Neupogen.
Désirée Caselli et al,Biosimilars in the management of neutropenia: focus on filgrastim.Biologics. 2016; 10: 1722.
M. Brito et al, Comparison of effectiveness of biosimilar filgrastim (Nivestim), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.Support Care Cancer. 2016 Feb;24(2):597-603
Désirée Caselli et al,Biosimilars in the management of neutropenia: focus on filgrastim.Biologics. 2016; 10: 1722.
Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. Support Care Cancer. 2014 Dec;22(12):3275-85.